140 related articles for article (PubMed ID: 29848679)
1. mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.
Koletsa T; Petrakis G; Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2018 Jun; 38(6):3319-3322. PubMed ID: 29848679
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
3. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of selected phosphoproteins of the mTOR signalling pathway in canine cutaneous squamous cell carcinoma.
Sanz Ressel BL; Massone AR; Barbeito CG
Vet J; 2019 Mar; 245():41-48. PubMed ID: 30819424
[TBL] [Abstract][Full Text] [Related]
5. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior.
Ferrandiz-Pulido C; Masferrer E; Toll A; Hernandez-Losa J; Mojal S; Pujol RM; Ramon y Cajal S; de Torres I; Garcia-Patos V
J Urol; 2013 Dec; 190(6):2288-95. PubMed ID: 23764082
[TBL] [Abstract][Full Text] [Related]
6. PI3K-AKT-mTOR pathway proteins are differently expressed in oral carcinogenesis.
Martins F; de Sousa SC; Dos Santos E; Woo SB; Gallottini M
J Oral Pathol Med; 2016 Nov; 45(10):746-752. PubMed ID: 26991907
[TBL] [Abstract][Full Text] [Related]
7. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
8. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
9. Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.
Balagula Y; Kang S; Patel MJ
Photodermatol Photoimmunol Photomed; 2015 Jan; 31(1):15-25. PubMed ID: 24517835
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of EGFR-PI3K-pAKT-mTOR-pS6 pathway in sinonasal squamous cell carcinomas.
Muñoz-Cordero MG; López F; García-Inclán C; López-Hernández A; Potes-Ares S; Fernández-Vañes L; Llorente JL; Hermsen M
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(1):16-24. PubMed ID: 29573781
[TBL] [Abstract][Full Text] [Related]
11. Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.
Darido C; Georgy SR; Cullinane C; Partridge DD; Walker R; Srivastava S; Roslan S; Carpinelli MR; Dworkin S; Pearson RB; Jane SM
Cell Death Differ; 2018 Jun; 25(6):1146-1159. PubMed ID: 29238073
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
13. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
14. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
15. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.
Liu FY; Zhao ZJ; Li P; Ding X; Zong ZH; Sun CF
Br J Oral Maxillofac Surg; 2010 Jun; 48(4):291-6. PubMed ID: 19615795
[TBL] [Abstract][Full Text] [Related]
18. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
19. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.
Dickinson SE; Janda J; Criswell J; Blohm-Mangone K; Olson ER; Liu Z; Barber C; Petricoin EF; Calvert VS; Einspahr J; Dickinson JE; Stratton SP; Curiel-Lewandrowski C; Saboda K; Hu C; Bode AM; Dong Z; Alberts DS; Timothy Bowden G
Cancer Prev Res (Phila); 2016 Mar; 9(3):215-24. PubMed ID: 26801880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
